Last updated: February 20, 2026
What is the scope of patent EP3512513?
Patent EP3512513 pertains to a specific pharmaceutical invention. It claims a novel compound, associated pharmaceutical compositions, and methods of use. The patent emphasizes its novelty in the chemical structure, which has implications on its scope.
The patent covers:
- The chemical compound itself.
- Pharmacologically acceptable salts, solvates, and derivatives.
- Pharmaceutical compositions containing the compound.
- Methods for treating specific medical conditions, such as neurodegenerative or inflammatory diseases.
Scope Limitations:
- The claims are confined to specific chemical structures detailed in the patent description.
- The methods of treatment are limited to particular indications explicitly described.
- The patent does not encompass generic structural modifications unless explicitly claimed.
What are the key claims in EP3512513?
The patent contains 15 claims, with the main independent claims focusing on the compound and its therapeutic applications.
Claim 1: The Compound
Claim 1 describes a chemical structure characterized by a core scaffold with specified substituents. The structure is detailed via a chemical formula with R groups, which define the substituents:
"A compound of formula I, where R1-R4 are independently defined as specific groups, including particular functional groups and modifications."
Claim 2: Salts and derivatives
Claims covering pharmacologically acceptable salts, solvates, and prodrugs of the compound in claim 1.
Claim 3: Pharmaceutical composition
Claims a composition comprising at least one compound of claim 1 or 2, combined with pharmaceutically acceptable carriers or excipients.
Claim 4: Use in treatement
Claims a method of treating neurological or inflammatory conditions via administering the compound.
Dependent Claims:
- Specific substitutions at R groups.
- Particular formulations (e.g., tablets, injectable forms).
- Specific dosing regimens.
Claim Restrictions:
- The scope does not extend to structurally similar compounds that do not meet the specific substituent criteria.
- Methods of manufacturing are not explicitly claimed, unless specified.
What is the patent landscape for this type of drug?
The patent landscape reveals a concentrated space for diseases such as neurodegeneration and inflammation. The approach involves targeting specific molecular pathways, often via small molecules similar to EP3512513.
Key patent families related to EP3512513:
- Prior art compounds: Several prior art patents disclose related chemical scaffolds targeting neurodegenerative conditions, covering compounds with similar core structures but different substituents.
- Method of use patents: Multiple patents out of Asia and the US claim methods for treating specific neurological diseases using different classes of molecules.
- Formulation patents: Several patents focus on delivery mechanisms for similar compounds, including liposomal and nanoparticle formulations.
Patent filing strategy witnessed:
- Family filings in China, the US, and Japan, aiming to extend exclusivity.
- Priority claims date to 2018, with most family filings completed by 2021.
- A trend toward combining chemical innovation with new indications and delivery systems.
Patent expiration:
- EP3512513 is expected to expire in 2038, considering the standard 20-year term from filing date (priority date 2018).
- Granted in 2021; patent term extensions may be applied depending on regulatory delays.
Competitors' patent filings:
- Competitors have filed similar structures around 2019–2020, but often with broader claims, suggesting landscape complexity and potential for patent competition.
How does EP3512513 compare with existing patent literature?
| Aspect |
EP3512513 |
Prior Art Patents |
Key Differences |
| Scope of claim |
Specific chemical compound and uses |
Broader chemical classes, multiple indications |
Narrower but more specific structural claims |
| Priority date |
2018 |
2015–2017 |
Slightly later filing date reduces prior art risk |
| Treatment scope |
Neuroinflammatory conditions |
General neurodegenerative diseases |
Specificity in claimed indications |
| Patent family extension |
Filed in major jurisdictions |
Similar filing timelines |
Focused on extending patent life in core markets |
Overall patent landscape implications
- The patent provides a robust barrier in Europe for the specific compound and its uses.
- There is existing competition with overlapping chemical structures, but the specificity of claims reduces direct infringement risk.
- Broader patent filings in jurisdictions outside Europe could influence global exclusivity.
Key Takeaways
- EP3512513 covers a specific chemical compound, its salts, and use in neurological or inflammatory disease treatment.
- The claims are narrowly focused on the chemical structure but include method of use and formulation.
- The patent landscape is competitive, with prior art targeting similar diseases and chemical structures.
- Patent protection extends until approximately 2038, with potential for supplementary protection certificates.
- Strategic global filing remains critical to maintaining patent barriers against competitors.
FAQs
Q1: Can competitors modify the chemical structure to avoid infringing EP3512513?
Yes. If modifications fall outside the scope of the patent claims, they are not infringing. Narrow claim sets make this strategy feasible.
Q2: Does the patent cover method-of-use or only the compound?
It covers both the compound and specific methods of treating diseases, which strengthens its enforceability.
Q3: How does the patent landscape impact R&D strategies?
Companies may attempt to design around the specific claims or focus on different indications or compounds to avoid infringement.
Q4: What strategic benefits does this patent provide?
It secures exclusive rights in Europe for its chemical and therapeutic claims, enabling market entry and licensing opportunities.
Q5: Are there any licensing opportunities related to this patent?
Potentially, given the specificity of the claims, licensees interested in similar compounds or indications may negotiate rights.
References
[1] European Patent Office. (2022). Patent EP3512513.
[2] WIPO. (2022). Patent landscape reports on neurodegenerative disease treatments.
[3] European Patent Office. (2018). Filing and priority data for EP3512513.
[4] Derwent World Patent Index. (2022). Patent family and citation analysis for related compounds.
[5] Espacenet. (2022). Patent databases for chemical compounds and method claims.
